Role of T cells in the pathogenesis of mucous membrane pemphigoid

Expert Review of Dermatology

Volumn 1, Issue 1, 2006, Pages 25-30

  Black, Antony P ^a   Wojnarowska, Fenella ^b   Ogg, Graham S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

antibodies; bullous; cicatricial; hemidesmosome; pemphigoid; skin; T cells

Indexed keywords

EID: 73549122443     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.1.1.25     Document Type: Article

References (44)

1. Bagan J, Muzio L, Scully C. Number III Mucous membrane pemphigoid. Oral Dis. 11 (4), 197–218 (2005).
2. Li K, Guidice GJ, Tamai K et al. Cloning of partial cDNA for mouse 180-kDa bullous pemphigoid antigen (BPAG2), a highly conserved collagenous protein of the cutaneous basement membrane zone. J. Invest. Dermatol. 99 (3), 258–263 (1992).
3. Balding SD, Prost C, Diaz LA et al. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J. Invest. Dermatol. 106 (1), 141–146 (1996).
4. Schumann H, Baetge J, Tasanen K et al. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am. J. Pathol. 156 (2), 685–695 (2000).
5. Leverkus M, Bhol K, Hirako Y et al. Cicatricial pemphigoid with circulating autoantibodies to beta4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230. Br. J. Dermatol. 145 (6), 998–1004 (2001).
6. Schmidt E, Skrobek C, Kromminga A et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br. J. Dermatol. 145 (5), 778–783 (2001).
7. Kromminga A, Sitaru C, Meyer J et al. Cicatricial pemphigoid differs from bullous pemphigoid and pemphigoid gestationis regarding the fine specificity of autoantibodies to the BP180 NC16A domain. J. Dermatol. Sci. 28 (1), 68–75 (2002).
8. Bhol KC, Goss L, Kumari S, Colon JE, Ahmed AR. Autoantibodies to human α6 integrin in patients with oral pemphigoid. J. Dent. Res. 80 (8), 1711–1715 (2001).
9. Lazarova Z, Hsu R, Yee C, Yancey KB. Anti-epiligrin cicatricial pemphigoid represents an autoimmune response to subunits present in laminin 5 (α3β3γ). Br. J. Dermatol. 139 (5), 791–797 (1998).
10. Chan LS, Ahmed AR, Anhalt GJ et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch. Dermatol. 138 (3), 370–379 (2002).
11. Bedane C, Prost C, Bernard P et al. Cicatricial pemphigoid antigen differs from bullous pemphigoid antigen by its exclusive extracellular localization: a study by indirect immunoelectronmicroscopy. J. Invest. Dermatol. 97 (1), 3–9 (1991).
12. Bernard P, Prost C, Aucouturier P et al. The subclass distribution of IgG autoantibodies in cicatricial pemphigoid and epidermolysis bullosa acquisita. J. Invest. Dermatol. 97 (2), 259–263 (1991).
13. Setterfield J, Shirlaw PJ, Kerr-Muir M et al. Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease. Br. J. Dermatol. 138 (4), 602–610 (1998).
14. Lazarova Z, Yee C, Darling T, Briggaman RA, Yancey KB. Passive transfer of antilaminin 5 antibodies induces subepidermal blisters in neonatal mice. J. Clin. Invest. 98 (7), 1509–1518 (1996).
15. Chan RY, Bhol K, Tesavibul N et al. The role of antibody to human β4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid. Invest. Ophthalmol. Vis. Sci. 40 (10), 2283–2290 (1999).
16. Colon JE, Bhol KC, Razzaque MS, Ahmed AR. In vitro organ culture model for mucous membrane pemphigoid. Clin. Immunol. 98 (2), 229–234 (2001).
17. Schmidt E, Reimer S, Kruse N et al. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J. Invest. Dermatol. 115 (5), 842–848 (2000).
18. Schmidt E, Wehr B, Tabengwa EM et al. Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. Clin. Exp. Immunol. 135 (3), 497–504 (2004).
19. Liu Z, Giudice GJ, Swartz SJ et al. The role of complement in experimental bullous pemphigoid. J. Clin. Invest. 95 (4), 1539–1544 (1995).
20. Liu Z, Giudice GJ, Zhou X et al. A major role for neutrophils in experimental bullous pemphigoid. J. Clin. Invest. 100 (5), 1256–1263 (1997).
21. Liu Z, Shipley JM, Vu TH et al. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J. Exp. Med. 188 (3), 475–482 (1998).
22. Liu Z, Shapiro SD, Zhou X et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J. Clin. Invest. 105 (1), 113–123 (2000).
23. Gammon WR, Merritt CC, Lewis DM et al. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J. Invest. Dermatol. 78 (4), 285–290 (1982).
24. Bernauer W, Wright P, Dart JK, Leonard JN, Lightman S. Cytokines in the conjunctiva of acute and chronic mucous membrane pemphigoid: an immunohistochemical analysis. Graefes Arch. Clin. Exp. Ophthalmol. 231 (10), 563–570. (1993).
25. Elder MJ, Lightman S. The immunological features and pathophysiology of ocular cicatricial pemphigoid. Eye 8 (2), 196–199. (1994).
26. Czech W, Schaller J, Schopf E, Kapp A. Granulocyte activation in bullous diseases: release of granular proteins in bullous pemphigoid and pemphigus vulgaris. J. Am. Acad. Dermatol. 29 (2 Pt 1), 210–215 (1993).
27. Borrego L, Maynard B, Peterson EA et al. Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am. J. Pathol. 148 (3), 897–909 (1996).
28. Delgado JC, Turbay D, Yunis EJ et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc. Natl Acad. Sci. USA 93 (16), 8569–8571 (1996).
29. Yunis JJ, Mobini N, Yunis EJ et al. Common major histocompatibility complex class II markers in clinical variants of cicatricial pemphigoid. Proc. Natl Acad. Sci. USA 91 (16), 7747–7751 (1994).
30. Setterfield J, Theron J, Vaughan RW et al. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br. J. Dermatol. 145 (3), 406–414 (2001).
31. Bernard A, Coitot S, Bremont A, Bernard G. T and B-cell co-operation: a dance of life and death. Transplantation 79 (Suppl. 3), S8 –S11 (2005).
32. Datta SK, Zhang L, Xu L. T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens. J. Mol. Med. 83 (4), 267–278 (2005).
33. Goodnow CC, Sprent J, de St Groth BF, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435 (7042), 590–597 (2005).
34. Aho S, Uitto J. 180-kD bullous pemphigoid antigen/type XVII collagen: tissue-specific expression and molecular interactions with keratin 18. J. Cell Biochem. 72 (3), 356–367 (1999).
35. + regulatory T-cells control autoimmunity? Curr. Opin. Immunol. 17 (6), 638–642 (2005).
36. Teraki Y, Hotta T, Shiohara T. Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells. J. Invest. Dermatol. 117 (5), 1097–1102 (2001).
37. Gombert M, Dieu-Nosjean MC, Winterberg F et al. CCL1-CCR8 interactions: an axis mediating the recruitment of T-cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J. Immunol. 174 (8), 5082–5091 (2005).
38. Black AP, Seneviratne SL, Jones L et al. Rapid effector function of circulating NC16A-specific T-cells in individuals with mucous membrane pemphigoid. Br. J. Dermatol. 151 (6), 1160–1164 (2004).
39. Caproni M, Calzolari A, Salvatore E et al. Cytokine profile and supposed contribution to scarring in cicatricial pemphigoid. J. Oral Pathol. Med. 32 (1), 34–40 (2003).
40. Eming R, Budinger L, Riechers R et al. Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay. Br. J. Dermatol. 143 (6), 1279–1282 (2000).
41. Budinger L, Borradori L, Yee C et al. Identification and characterization of autoreactive T-cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J. Clin. Invest. 102 (12), 2082–2089 (1998).
42. Lin MS, Fu CL, Giudice GJ et al. Epitopes targeted by bullous pemphigoid T-lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J. Invest. Dermatol. 115 (6), 955–961 (2000).
43. Hacker-Foegen MK, Zillikens D, Giudice GJ, Lin MS. T-cell receptor gene usage of BP180-specific T-lymphocytes from patients with bullous pemphigoid and pemphigoid gestationis. Clin. Immunol. 113 (2), 179–186 (2004).
44. Rico MJ, Streilein RD, Hall RP III. Peripheral blood mononuclear cells from patients with bullous pemphigoid have an increased frequency of response to synthetic peptides encoded by BPAG1. J. Invest. Dermatol. 103 (1), 73–77 (1994).